Morning Rounds: News From August 3-9
• Bipartisan House Armed Services Committee amendments propose using the 2027 National Defense Authorization Act to extend military clinical trials of MDMA and psilocybin for active-duty service members. • Louisiana launched a regulated clinical pilot program this week using psilocybin and related compounds to treat substance use and treatment-resistant mental health conditions, funded by opioid-settlement money. • The FDA has approved oveporexton for narcolepsy type 1, marking the first medication capable of treating the full range of NT1 symptoms.
psychiatrictimes.com











